Teijin Pharma inks exclusive license deal with Novartis

6 March 2023

Japan’s Teijin Parma has entered into an exclusive global license agreement with Swiss pharma giant Novartis (NOVN: VX) to research, develop, manufacture and commercialize an investigational pre-clinical candidate for proteinuric kidney diseases.

The investigational small molecule candidate was discovered at the Teijin Institute for Bio-medical Research, Teijin’s drug development base in Tokyo. The candidate acts in a genetically validated pathway and is believed to impact the pathogenesis of multiple kidney diseases.

This deal comes about since Novartis made the decision to divest its clinical non-alcoholic steatohepatitis (NASH) assets as part of its new strategy focusing on five core therapeutic segments: cardiovascular, hematology, solid tumors, immunology and neuroscience. Novartis last month announced it was pulling out of a NASH collaboration with US biotech Pliant Therapeutics (Nasdaq: PLRX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK